Gosset Ownership
Private
Employees
~1
Therapeutic Areas
Stage
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
PellePharm General Information
PellePharm has completed enrollment for a Phase 2 clinical trial in Gorlin Syndrome and was preparing to commence a pivotal Phase 3 trial in early 2019. Their topical patidegib gel has shown early promise in Phase 2 clinical studies for the mitigation of BCC tumors in Gorlin Syndrome.
Contact Information
Primary Industry
Biotech
Corporate Office
San Francisco, California
United States
United States
Drug Pipeline
patidegib
Phase 3Key Partnerships
LEO Pharma
PellePharm Funding
No funding data available
To view PellePharm's complete valuation and funding history, request access »